Last reviewed · How we verify
NCT02774460: PHYSIC
The Precision Hypertension Care Study
Phase 4 trial testing Zestril® in Hypertension in 280 participants. Completed in 11 June 2021.
11 June 2021
Quick facts
| Lead sponsor | Uppsala University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 280 |
| Start date | 20 February 2017 |
| Primary completion | 11 June 2021 |
| Estimated completion | 11 June 2021 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Zestril® — full drug profile →
- Atacand® — full drug profile →
- Norvasc®
- Hydrochlorthiazide® — full drug profile →
- Treatment X — full drug profile →
- Treatment Y — full drug profile →
- Placebo
Conditions studied
- Hypertension — all drugs for Hypertension →
Sponsor
Uppsala University
Who can join
Adults 40 to 75, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The PHYSIC study aims to investigate the potential for precision medicine in the treatment of high blood pressure. It is a double-blind, randomized, repeated cross-over trial with six treatment periods: four classes of blood pressure-lowering drugs where treatment with two classes are repeated for each patient. The classes of blood pressure-lowering drugs to be tested are a diuretic, a calcium channel blocker, an ACE-inhibitor and an angiotensin receptor blocker.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02774460
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Uppsala University trials
Trials by the same sponsor.
- NCT07517185 — The HIt HArd and hiT Early in Multiple Sclerosis Trial · Phase 2 · not yet recruiting
- NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
- NCT07461636 — Robotic-Assisted Pedicle Screw Placement in Spine Surgery · recruiting
- NCT07273409 — Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not · NA · recruiting
- NCT07352683 — Open TAP-block in Pediatric Abdominal Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02774460 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uppsala University
- Last refreshed: 1 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02774460.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing